VIVA-Asia Rare Tumor Board Webinar
CNS Atypical Teratoid/Rhabdoid Tumor (ATRT)
Thursday, 16 May 2024 | 8.00PM - 9.00PM (UTC+8 | SGT) | Check your Time Zone
VIVA-ASIA RARE TUMOR BOARD WEBINAR is a virtual quarterly meeting that is organized by VIVA Foundation for Children with Cancer to enable doctors from all over the world to discuss the diagnosis and treatment of rare pediatric tumors.
Join us for a discussion on Thursday, 16 May 2024, 8:00PM - 9.00PM (UTC +8), on the topic of CNS Atypical Teratoid/Rhabdoid Tumor (ATRT).
We're privileged to welcome Dr Zhu MO from The University of Hong Kong - Shenzhen Hospital, Shenzhen, Dr Dennis KU from Hong Kong Children’s Hospital, Hong Kong, and Dr Annie HUANG from The Hospital of Sick Children, Toronto, who will share with us their invaluable insights and experiences.
This is an excellent opportunity to learn from experts in the field and to ask questions about rare tumors. We hope that you will join us for this important meeting.
Medical professionals in Singapore may eligible for CME/CPE/CNE credits for attending this webinar.
PROGRAMME RUNDOWN
PRESENTATION SUMMARIES
Case Presentation by Dr Mo, Zhu
A male child, aged 10 years and 8 months now, began experiencing high fever and loss of consciousness at 1 year and 8 months old. Local hospital examination revealed a pineocytoma (WHO GRADE I), which was treated with surgery and chemotherapy, resulting in remission. During a follow-up at 3 years and 4 months, another CNS tumor was discovered in the fourth ventricle. After surgical removal, the child was referred to University of Hong Kong - Shenzhen Hospital, where the pathological diagnosis was Atypical Teratoid/Rhabdoid Tumor (ATRT, WHO GRADE IV). Following the surgery, the child underwent chemotherapy and radiotherapy according to the ATRT04-DDCMV protocol. Up to now, the child has experienced multiple recurrences, including 5 surgeries and 6 radiotherapy sessions. He is currently undergoing maintenance chemotherapy with the MEMMAT protocol.
Novel Therapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) by Dr Ku, Dennis
ATRT exhibits a less favorable prognosis in comparison to other CNS embryonal tumors, even with the application of intensive treatment. However, with recent advancements in the molecular subgrouping of ATRT and enhanced understanding at the molecular level, novel treatment approaches and clinical trials are rapidly emerging. This presentation aims to provide a concise overview of the innovative therapies being developed for ATRT.
WATCH IT AGAIN
SPEAKERS
Dr Huang, Annie
Associate Chair Research, Pediatrics
Tier 1 Canada Research Chair in Rare Childhood Brain Tumors
Professor of Paediatrics, Medical Biophysics, Lab Medicine & Pathobiology
University of Toronto
Pediatric Neuro-oncologist, Pediatric Brain Tumour Program
Senior Scientist, Program in Cell Biology
Arthur and Sonia Labatt Brain Tumour Research Centre
The Hospital for Sick Children Research Institute
Canada
Dr Mo, Zhu
The University of Hong Kong – Shenzhen Hospital
China
Dr Ku, Dennis
Consultant
Department of Haematology and Oncology
Hong Kong Children's Hospital
Hong Kong
CONVENORS
Prof Chan, Godfrey
Honorary Professor, Department of Paediatrics and Adolescent Medicine
School of Clinical Medicine, The University of Hong Kong
Consultant Paediatric Haematologist Oncologist
Hong Kong Sanatorium and Hospital
Hong Kong SAR
Dr Liu, Anthony
Honorary Clinical Assistant Professor
Department of Paediatrics & Adolescent Medicine
LKS Faculty of Medicine, The University of Hong Kong
Hong Kong SAR
Staff Oncologist, Pediatric Brain Tumour Program
The Hospital for Sick Children, Toronto
Canada